Navigation Links
Novexel Strengthens its Scientific Advisory Board With the Appointment of Dr. Karen Bush
Date:3/26/2009

PARIS, March 26 /PRNewswire-FirstCall/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces today the appointment of Dr. Karen Bush to the Company's Scientific Advisory Board (SAB). Novexel's SAB is chaired by Dr. David Shlaes who sits on the Company's board. Dr. Bush, who is currently Adjunct Professor at the Department of Biology at Indiana University, brings extensive experience and knowledge of the anti-infectives field to Novexel's SAB.

Dr. Bush's distinguished scientific career in anti-infective research and development spans over three decades and she is a recognised authority in the study of resistance mediated by beta-lactamases. During her career, Dr. Bush has held the position of Distinguished Research Fellow at Johnson & Johnson, Director of Microbial Biochemistry at the Astra Research Center, Boston, MA; Senior Research Fellow, Infectious Disease at Wyeth and Principal Investigator at the Department of Microbiology at Bristol Myers Squibb. Over this period, Dr. Bush was a member of the scientific teams that developed a portfolio of leading hospital antibiotics including levofloxacin (Levaquin), doripenem (Doribax). aztreonam (Azactam) and piperacillin-tazobactam (Zozyn).

Dr. Bush received her Ph.D. from the Indiana University Chemistry Department in 1970 and has since authored over 160 peer-reviewed publications and 17 book chapters. Dr. Bush has also served on the Editorial Boards of several internationally renowned journals including Antimicrobial Agents and Chemotherapy and the European Journal of Clinical Microbiology and Infectious Diseases. Dr. Bush is a member of the Program Committee for one of the anti-infectives industry's most important conferences, the Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC. Moreover, Dr. Bush was elected a Fellow of the American Academy of Microbiology in 2000, in recognition of her record of scientific achievement and original contributions to microbiology

About Novexel

Novexel is a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The ever increasing resistance to marketed antibiotics has led to a clear need for novel drugs that are active against multi-drug resistant bacteria. Novexel's products are targeting the global hospital antibiotic market, which was worth an estimated $17bn in 2008.[1]

Novexel currently has two novel antibacterials in Phase II clinical development. These are the injectable beta-lactamase inhibitor, NXL104, which is being developed in combination with the cephalosporin antibiotic ceftazidime for serious Gram negative infections, and the oral streptogramin antibiotic, NXL103, for the treatment of Gram positive infections, with a focus on treatment in the hospital setting and intravenous (IV) to oral switch. Novexel has three further programmes in preclinical development, NXL105, a novel anti-Pseudomonal antibiotic, NXL201, a novel echinocandin antifungal agent, and NXL104 in combination with ceftaroline. This latter product is being developed by our partner, Forest Laboratories, solely for North American markets.

Novexel was created in December 2004 as an independent spin-out of the sanofi-aventis (Euronext Paris: SAN, NYSE: SNY) anti-infectives unit. Novexel has a team of 50 employees with significant experience in anti-infective research and development, who are located in Paris, France and Philadelphia, USA.

    [1] Source: IMS Health, MIDAS, 2006-2008

    For further information please contact:

    Novexel
    Gordon Waldron, CFO
    gordon.waldron@novexel.com

    Citigate Dewe Rogerson
    Amber Bielecka/David Dible/Nina Enegren
    Tel.: +44-(0)207-638-95-71
    amber.bielecka@citigatedr.co.uk



'/>"/>
SOURCE Novexel
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Karolinska Development Strengthens its Management Team With the Appointment of Dr Carl Harald Janson
2. Caliper Life Sciences Reports Third Quarter 2008 Results; Sharpens Growth Focus, Strengthens Balance Sheet and Reduces Costs
3. Trillium Strengthens its Board of Directors
4. Prometheus Strengthens Intellectual Property Portfolio with Newly Issued Patents for Thiopurine Metabolite Testing
5. Ikaria Strengthens Executive Leadership Team
6. Algenol Biofuels Further Strengthens Team With Key Appointments
7. InNexus Biotechnology Strengthens Patent Team With New Leadership
8. InVitria Further Strengthens Sales Team with Promotion of Brandy Sargent to Account Manager - Western United States
9. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
10. Ikaria(R) Strengthens Commercial Operations and Human Resources Leadership
11. Milestone Biosciences, LLC Further Strengthens Executive Management Team
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering with experienced ... this eBook by providing practical tips, tools, and strategies for clinical researchers. , ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
Breaking Biology Technology:
(Date:6/2/2016)... NEW YORK , June 2, 2016   The ... (Weather), is announcing Watson Ads, an industry-first capability in which ... advertising, by being able to ask questions via voice or ... Marketers have long ... with the consumer, that can be personal, relevant and valuable; ...
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... MINNEAPOLIS , May 20, 2016  VoiceIt ... technology partnership with VoicePass. By working ... user experience.  Because VoiceIt and VoicePass take slightly ... two engines increases both security and usability. ... expressed excitement about this new partnership. ...
Breaking Biology News(10 mins):